Xue Yanwen, Peng Xiaoxiang, Yan Meng, Du Yanan, Cao Yahui, Zhao Ronglan
School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Shandong Advanced Academy Engineering Research Institute of Precision Medicine Innovation and Transformation of Infections Diseases, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Purinergic Signal. 2025 Aug 22. doi: 10.1007/s11302-025-10108-4.
The P2X7 receptor is a trimeric ion channel purinergic receptor. It plays a crucial part in the pathophysiology of cancers and a variety of inflammatory diseases and is widely expressed in different cell types. Leukemia represents a type of malignant clonal disorder that impacts the hematopoietic stem cells. Chemotherapy is one of the main treatment methods for leukemia, but there are also many side effects. In recent years, targeted therapy is a new treatment method. Research has shown that the progression and occurrence of leukemia is significantly related to the P2X7 receptor. The P2X7 receptor is also involved in the migration and invasion of leukemia cells. Furthermore, the polymorphism of the P2X7 receptor gene also takes on a significant function in the occurrence, development and clinical course of leukemia patients. The P2X7 receptor inhibitors have been found to work better in combination with existing therapeutics. Therefore, the P2X7 receptor may serve as a potential therapeutic target.
P2X7受体是一种三聚体离子通道嘌呤能受体。它在癌症和多种炎症性疾病的病理生理学中起着关键作用，并在不同细胞类型中广泛表达。白血病是一种影响造血干细胞的恶性克隆性疾病。化疗是白血病的主要治疗方法之一，但也有许多副作用。近年来，靶向治疗是一种新的治疗方法。研究表明，白血病的进展和发生与P2X7受体显著相关。P2X7受体还参与白血病细胞的迁移和侵袭。此外，P2X7受体基因的多态性在白血病患者的发生、发展和临床病程中也具有重要作用。已发现P2X7受体抑制剂与现有治疗方法联合使用效果更佳。因此，P2X7受体可能是一个潜在的治疗靶点。
